- Net revenue of $41.1 million increased 25% over the prior year
period
- Adjusted EBITDA1 of $3.5 million versus $(2.9) million over the
prior year period
- Established European foothold with a strategic investment in
Sanity Group, a leading German cannabis company
- Completed landmark clinical study on FAST™ nanoemulsion
technology showing faster onset, improved bioavailability of
ingestible products
- Pro-forma cash position of $173 million2
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the
“Company” or “Organigram”), a leading licensed producer of
cannabis, announced its results for the third quarter ended June
30, 2024 (“Q3 Fiscal 2024”).
THIRD QUARTER HIGHLIGHTS
- Third quarter net revenue increased 25% to $41.1 million
compared to $32.8 million in the same prior-year period
- Adjusted gross margin1 of $14.6 million or 36%, compared to
$6.1 or 19% in the same prior- year period
- Net income of $2.8 million, compared to a loss of $213.5
million in same prior-year period
- Adjusted EBITDA1 increased to $3.5 million in the third quarter
compared to a loss of $2.9 million in the same prior-year
period
- Pro-forma cash position of approximately $173 million2
- Held the #1 position in milled flower, #1 in hash, #1 in pure
CBD gummies, #3 in edibles, #3 in pre-rolls, #3 in dried flower,
and held the overall #3 market position in Canada3
- #1 market share position in Atlantic Canada, #3 in Ontario, and
a top 5 licensed producer in every Canadian province3
- Achieved 9.3% market share in Quebec in Q3 Fiscal 2024, up from
8.2% in Q2 Fiscal 20243
- Achieved record market share in New Brunswick of 25.8% in Q3
Fiscal 2024, up from 20% in Q2 Fiscal 20243
- The Company made its first significant European strategic
investment to expand its presence in the European cannabis market
by acquiring a minority stake in Berlin-based cannabis company
Sanity Group GmbH ("Sanity Group") from existing founders and
shareholders for €2.5 million, and advancing €11.5 million to
Sanity Group by way of an unsecured convertible note, for a total
initial investment of €14 million (approximately $21 million).
Sanity Group is a leading German cannabis company with a robust
distribution network, collaborating with over 2,000 pharmacies and
approximately 5,000 physicians across the high growth German
market
- Signed two new international supply agreements in Australia and
the U.K. The Company now has supply agreements with seven partners
in Germany, U.K., Australia and Israel and is evaluating additional
global partnership opportunities
- The Company's first three seed-based production rooms have been
successfully harvested, with an average yield of 200g per plant and
average THC potency of 25.5%. Four more rooms were harvested in
July and the Company aims to increase seed-based production to
approximately 30% by the end of calendar 2024
- Subsequent to quarter end, the Company strengthened its
auto-flower and rare cannabinoid portfolio through an accelerated
partial funding of the final Phylos investment tranche. The
remainder of the investment will be funded upon completion of newly
expanded milestones that included expanded licensing for
high-potency CBD, CBG, CBC, and CBDV cultivars, and delivery of two
cohorts of unique, auto-flower seed varietals
- Organigram was recognized for Executive Gender Diversity by the
Globe & Mail’s Women Lead Here Report for the fourth
consecutive year
“We are pleased to report a strong third quarter, highlighted by
a 25% year-over-year increase in net revenue, and a significant
improvement in adjusted EBITDA”, said Beena Goldenberg, Chief
Executive Officer. “Our strategic investments and partnerships,
both domestically and internationally, have positioned us for
growth and diversification, particularly in the European market
with our investment in Sanity Group. Furthermore, the preliminary
results from our landmark PK study on our latest patent pending
nanoemulsion technology demonstrate our ongoing commitment to
innovation and expanding our product offerings. I continue to be
very proud of our dedicated team for their hard work and
contributions to these achievements.”
Canadian Recreational Market Introduction Highlights
As an industry leader and pure-play cannabis company, Organigram
remains committed to delivering consumer focused innovations and
products to the Canadian market. Q3 Fiscal 2024 saw the
introduction of 18 new SKUs to the market for Organigram. Some
notable highlights include:
SHRED Tropic Thunder/Gnarberry Big Jar of
Joints combo pack - 28 x 0.5g joints
SHRED X Blue Razzberry Ice, Megamelon, and
Tiger Blood Heavies - Three new flavors of 3 x 0.5g infused
pre-rolls exceeding 40% THC
Trailblazer Sour OG Cookies and Lemonade Haze
- Two strains of premium, hang-dried, hand- groomed, slow-cured
cannabis, hand-packed in glass jars
Monjour Cherry Citrus Sunshine - Sugar coated
gummies featuring 30 mg THCV, 80 mg CBD, and 10 mg THC per pack
Research and Product Development
Product Development Collaboration ("PDC") and Centre of
Excellence ("CoE")
- Organigram and BAT continue to work together through their PDC
on new work streams to develop innovative technologies in the
edible, vape and beverage categories in addition to new disruptive
inhalation formats aimed at addressing the biggest consumer pain
points that exist in the category today
- Subsequent to quarter end, on August 7th, the Company unveiled
the preliminary results of a landmark clinical pharmacokinetic (PK)
study conducted via the PDC, on our latest innovation, nanoemulsion
technology. This patent-pending technology, branded as FAST™ (Fast
Acting Soluble Technology), will be the first innovation to be
commercialized by Organigram leveraging the output of the PDC
Jupiter Strategic Investment Pool
- As described above, the Company made its first significant
European strategic investment to expand its presence in the
European cannabis market with a C$21 million investment in Sanity
Group, a leading German cannabis company
- The Company is exploring U.S. and additional international
investment opportunities that align with Organigram’s strategy to
increase market share, enhance profitability, and establish itself
as a global industry leader, with the goal of delivering long-term
shareholder value
International Sales
- The Company signed two new international supply agreements in
Australia and in the U.K.
- The Company now has supply agreements with seven partners in
Germany, U.K., Australia and Israel and is evaluating additional
global partnership opportunities
Balance Sheet and Liquidity
- As of June 30, 2024, the Company had cash (restricted &
unrestricted) of $89.5 million
- In April 2024, the Company closed an oversubscribed
underwritten overnight financing for gross proceeds of $28.8
million at $3.23 per unit
- On a pro-forma basis, Organigram will have a cash position of
approximately $173 million2 upon closing of the remaining BAT's
follow-on strategic investment tranches
Third Quarter 2024 Financial Overview
- Net revenue:
- Q3 Fiscal 2024 net revenue increased 25% to $41.1 million, from
$32.8 million in Q3 Fiscal 2023, primarily due to an increase in
recreational cannabis sales
- Gross margin:
- Q3 Fiscal 2024 cost of sales decreased to $27.2 million, from
$32.3 million in Q3 Fiscal 2023, primarily due to greater scale and
operating efficiencies, which resulted in lower costs per unit
- Q3 Fiscal 2024 adjusted gross margin4 was $14.6 million, or 36%
of net revenue, compared to $6.1 million, or 19%, in Q3 Fiscal
2023. The increase is attributable to several factors, including
lower cultivation and post-harvest costs, reduced inventory
provisions, lower depreciation resulting from impairment charges
recorded in fiscal year 2023, and higher recreational cannabis
revenue
- Selling, general & administrative ("SG&A") expenses:
- SG&A expenses for Q3 Fiscal 2024 were $14.8 million, a
decrease from $19.0 million in Q3 Fiscal 2023, representing a
decrease of 22% year-over year. The decrease was the result of
lower costs associated with the implementation of the first phase
of a new ERP system and reduced professional fees
- Net Income (loss):
- Q3 Fiscal 2024 net income was $2.8 million compared to a net
loss of $213.5 million in Q3 Fiscal 2023. The reduction in net loss
from the prior period is primarily attributable to higher revenues
from recreational cannabis revenue in Q3 Fiscal 2024, as well as an
impairment loss recorded in Q3 Fiscal 2023.
- Adjusted EBITDA5:
- Q3 Fiscal 2024 adjusted EBITDA was $3.5 million compared to
$(2.9) million in adjusted EBITDA in Q3 Fiscal 2023. The increase
was primarily attributable to higher revenues from recreational
cannabis in Q3 Fiscal 2024 and operational efficiency gains
- Net cash used in operating activities before working capital
changes:
- Q3 Fiscal 2024 net cash used by operating activities was $0.2
million, compared to $14.8 million cash used in Q3 Fiscal 2023,
which was primarily due to higher revenues from recreational
cannabis and reduced costs in Q3 Fiscal 2024.
Chief Financial Officer, Greg Guyatt commented, "We are pleased
with the results of our focus on operating efficiencies and
resulting margin improvements and positive adjusted EBITDA in the
quarter. With $173 million in pro-forma cash6, we believe we have
one of the strongest balance sheets in the industry and are well
positioned to capitalize on future growth opportunities."
Select Key Financial Metrics
(in $000s unless otherwise indicated)
Q3-2024
Q3-2023
% Change
Gross revenue
63,605
48,409
31
%
Excise taxes
(22,545
)
(15,624
)
44
%
Net revenue
41,060
32,785
25
%
Cost of sales
27,173
32,289
(16
)%
Gross margin before fair value changes to
biological assets & inventories sold
13,887
496
2700
%
Realized fair value on inventories sold
and other inventory charges
(13,728
)
(13,588
)
1
%
Unrealized gain on changes in fair value
of biological assets
13,849
8,395
65
%
Gross margin
14,008
(4,697
)
nm
Adjusted gross margin(1)
14,586
6,074
140
%
Adjusted gross margin %(1)
36
%
19
%
17
%
Selling (including marketing), general
& administrative expenses(2)
14,797
19,033
(22
)%
Net income (loss)
2,818
(213,451
)
nm
Adjusted EBITDA(1)
3,465
(2,914
)
nm
Net cash used in operating activities
before working capital changes
(182
)
(14,847
)
(99
)%
Net cash used in operating activities
after working capital changes
(3,730
)
(5,515
)
(32
)%
Note (1) Adjusted gross margin, adjusted
gross margin % and adjusted EBITDA are non-IFRS financial measures
not defined by and do not have any standardized meaning under IFRS
and might not be comparable to similar financial measures disclosed
by other issuers; please refer to “Non-IFRS Financial Measures” in
this press release for more information.
Note (2) Excluding non-cash share-based
compensation.
Select Balance Sheet Metrics (in
$000s)
JUNE 30, 2024
SEPTEMBER 30, 2023
% Change
Cash & short-term investments
(excluding restricted cash)
80,067
33,864
136
%
Biological assets & inventories
84,079
80,953
4
%
Other current assets
41,506
41,159
1
%
Accounts payable & accrued
liabilities
39,722
20,007
99
%
Current portion of long-term debt
61
76
(20
)%
Working capital
157,750
133,545
18
%
Property, plant & equipment
95,435
99,046
(4
)%
Long-term debt
39
79
(51
)%
Total assets
354,748
298,455
19
%
Total liabilities
58,892
26,832
119
%
Shareholders’ equity
295,856
271,623
9
%
The following table reconciles the Company's Adjusted EBITDA to
net loss.
Adjusted EBITDA Reconciliation
(in $000s unless otherwise indicated)
Q3-2024
Q3-2023
Net (loss) income as reported
$
2,818
$
(213,451
)
Add/(Deduct):
Financing costs, net of investment
income
(1,179
)
(903
)
Income tax (recovery) expense
—
(1,302
)
Depreciation, amortization, and (gain)
loss on disposal of property, plant and equipment (per statement of
cash flows)
2,332
6,975
Impairment of intangible assets
—
37,905
Impairment of property, plant and
equipment
—
153,337
Share of loss (gain) from investments in
associates and impairment loss (recovery) from loan receivable
122
287
Realized fair value on inventories sold
and other inventory charges
13,728
13,588
Unrealized gain on change in fair value of
biological assets
(13,849
)
(8,395
)
Share-based compensation (per statement of
cash flows)
2,087
1,325
Government subsidies, insurance recoveries
and other non-operating expenses
139
—
Share issuance costs allocated to
derivative warrant liabilities and change in fair value of
derivative liabilities, other financial assets and contingent
consideration
(6,241
)
(4,214
)
ERP implementation costs
7
2,561
Transaction costs
421
538
Provisions (recoveries) and net realizable
value adjustments related to inventory and biological assets
699
5,578
Research and development expenditures, net
of depreciation
2,381
3,257
Adjusted EBITDA
$
3,465
$
(2,914
)
The following table reconciles the Company's adjusted gross
margin to gross margin before fair value changes to biological
assets and inventories sold:
Adjusted Gross Margin Reconciliation
(in $000s unless otherwise indicated)
Q3-2024
Q3-2023
Net revenue
$
41,060
$
32,785
Cost of sales before adjustments
26,474
26,711
Adjusted gross margin
14,586
6,074
Adjusted gross margin %
36
%
19
%
Less:
Write-offs and impairment of inventories
and biological assets
628
2,823
Provisions to net realizable value
71
2,755
Gross margin before fair value
adjustments
13,887
496
Gross margin % (before fair value
adjustments)
34
%
2
%
Add:
Realized fair value on inventories sold
and other inventory charges
(13,728
)
(13,588
)
Unrealized gain on changes in fair value
of biological assets
13,849
8,395
Gross margin
14,008
(4,697
)
Gross margin %
34
%
(14
)%
Third Quarter Fiscal 2024 Conference Call
The Company will host a conference call to discuss its results
with details as follows: Date: August 13, 2024 Time: 8:00 am
Eastern Time
To register for the conference call, please use this link:
https://registrations.events/direct/Q4I9676663358
To ensure you are connected for the full call, we suggest
registering a day in advance or at minimum 10 minutes before the
start of the call. After registering, a confirmation will be sent
through email, including dial in details and unique conference call
codes for entry. Registration is open through the live call.
To access the webcast:
https://events.q4inc.com/attendee/291354315
A replay of the webcast will be available within 24 hours after
the conclusion of the call at https://www.organigram.ca/investors
and will be archived for a period of 90 days following the
call.
Non-IFRS Financial Measures
This news release refers to certain financial and operational
performance measures (including adjusted gross margin, adjusted
gross margin % and adjusted EBITDA) that are not defined by and do
not have a standardized meaning under International Financial
Reporting Standards (“IFRS”) as issued by the International
Accounting Standards Board. Non-IFRS financial measures are used by
management to assess the financial and operational performance of
the Company. The Company believes that these non-IFRS financial
measures, in addition to conventional measures prepared in
accordance with IFRS, enable investors to evaluate the Company’s
operating results, underlying performance and prospects in a
similar manner to the Company’s management. As there are no
standardized methods of calculating these non-IFRS measures, the
Company’s approaches may differ from those used by others, and
accordingly, the use of these measures may not be directly
comparable. Accordingly, these non-IFRS measures are intended to
provide additional information and should not be considered in
isolation or as a substitute for measures of performance prepared
in accordance with IFRS.
Adjusted EBITDA is a non-IFRS measure that the Company defines
as net income (loss) before: financing costs, net of investment
income; income tax expense (recovery); depreciation, amortization,
reversal of/or impairment, normalization of depreciation add-back
due to changes in depreciable assets resulting from impairment
charges, (gain) loss on disposal of property, plant and equipment
(per the statement of cash flows); share-based compensation (per
the statement of cash flows); share of loss (gain) from investments
in associates and impairment loss (recovery) from loan receivable;
change in fair value of contingent consideration; change in fair
value of derivative liabilities; expenditures incurred in
connection with research and development activities (net of
depreciation); unrealized (gain) loss on changes in fair value of
biological assets; realized fair value on inventories sold and
other inventory charges; provisions (recoveries) and net realizable
value adjustment related to inventory and biological assets;
government subsidies and insurance recoveries; legal provisions
(recoveries); incremental fair value component of inventories sold
from acquisitions; ERP implementation costs; transaction costs;
share issuance costs; and provision for Canndoc Ltd. expected
credit losses. Adjusted EBITDA is intended to provide a proxy for
the Company’s operating cash flow and derives expectations of
future financial performance for the Company, and excludes
adjustments that are not reflective of current operating
results.
Adjusted gross margin is a non-IFRS measure that the Company
defines as net revenue less cost of sales, before the effects of
(i) unrealized gain (loss) on changes in fair value of biological
assets; (ii) realized fair value on inventories sold and other
inventory charges; (iii) provisions (recoveries) of inventories and
biological assets; and (iv) provisions to net realizable value.
Adjusted gross margin percentage is a non-IFRS measure that the
Company calculates by dividing adjusted gross margin by net
revenue.
Management believes that this adjusted gross margin and adjusted
gross margin percentage both provide useful information to assess
the profitability of the Company's operations as they represent the
normalized gross margin generated from operations and exclude the
effects of non-cash fair value adjustments on inventories and
biological assets, which are required by IFRS.
The most directly comparable measure to adjusted EBITDA,
calculated in accordance with IFRS is net income (loss) and
beginning on page 6 of this press release is a reconciliation to
such measure. The most directly comparable measure to adjusted
gross margin calculated in accordance with IFRS is gross margin
before fair value adjustments and beginning on page 7 of this press
release is a reconciliation to such measure.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and
TSX listed company whose wholly-owned subsidiary, Organigram Inc.,
is a licensed producer of cannabis and cannabis-derived products in
Canada.
Organigram is focused on producing high-quality, indoor-grown
cannabis for adult recreational consumers in Canada, as well as
developing international business partnerships to extend the
Company’s global footprint. Organigram has also developed a
portfolio of legal adult-use recreational cannabis brands,
including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, Monjour
and Trailblazer. Organigram operates facilities in Moncton, New
Brunswick and Lac-Supérieur, Québec, with a dedicated manufacturing
facility in Winnipeg, Manitoba. The Company is regulated by the
Cannabis Act and the Cannabis Regulations (Canada).
Cautionary Note Regarding Forward Looking Statements
This news release contains forward-looking information.
Forward-looking information, in general, can be identified by the
use of forward-looking terminology such as “outlook”, “objective”,
“may”, “will”, “could”, “would”, “might”, “expect”, “intend”,
“estimate”, “anticipate”, “believe”, “plan”, “continue”, “budget”,
“schedule” or “forecast” or similar expressions suggesting future
outcomes or events. They include, but are not limited to,
statements with respect to expectations, projections or other
characterizations of future events or circumstances, and the
Company’s objectives, goals, strategies, beliefs, intentions,
plans, estimates, forecasts, projections and outlook, including
statements relating to the Company’s future performance, the
Company’s positioning to capture additional market share and sales
including international sales, the Company's expectations
concerning its strategic investment in Sanity Group, expectations
for consumer demand and international markets, expected increase in
SKUs, expected improvement to gross margins before fair value
changes to biological assets and inventories, expectations
regarding adjusted gross margins, adjusted EBITDA and net revenue
in Fiscal 2024 and beyond, the Company's ability to generate
consistent free cash flow from operations, expectations regarding
cultivation capacity, the Company’s plans and objectives including
around the CoE, the Company's expectations concerning its
nanoemulsion technology, availability and sources of any future
financing including satisfaction of closing conditions for future
tranches of the BAT follow-on investment, expectations related to
EU-GMP certification including timing and receipt, availability of
cost efficiency opportunities, expectations around lower product
cultivation costs, the ability to achieve economies of scale and
ramp up cultivation, expectations pertaining to the increase of
automation and reduction in reliance on manual labour, expectations
around the launch of higher margin dried flower strains,
expectations around market and consumer demand and other patterns
related to existing, new and planned product forms; timing for
launch of new product forms, ability of those new product forms to
capture sales and market share, estimates around incremental sales
and more generally estimates or predictions of actions of
customers, suppliers, partners, distributors, competitors or
regulatory authorities; continuation of shipments to existing and
prospective international jurisdictions and customers, statements
regarding the future of the Canadian and international cannabis
markets and, statements regarding the Company’s future economic
performance. These statements are not historical facts but instead
represent management beliefs regarding future events, many of
which, by their nature are inherently uncertain and beyond
management control. Forward-looking information has been based on
the Company’s current expectations about future events.
This news release contains information concerning our industry
and the markets in which we operate, including our market position
and market share, which is based on information from independent
third-party sources. Although we believe these sources to be
generally reliable, market and industry data is inherently
imprecise, subject to interpretation and cannot be verified with
complete certainty due to limits on the availability and
reliability of raw data, the voluntary nature of the data gathering
process, and other limitations and uncertainties inherent in any
statistical survey or data collection process. We have not
independently verified any third-party information contained
herein.
Forward-looking information involves known and unknown risks,
uncertainties and other factors that may cause actual events to
differ materially from current expectations. These risks,
uncertainties and factors include: general economic factors;
receipt of regulatory approvals, consents, and/or final
determinations, and any conditions imposed upon same and the timing
thereof; the Company's ability to meet regulatory criteria which
may be subject to change; change in regulation including
restrictions on sale of new product forms; timing for federal
legalization of cannabis in the U.S. and changing regulatory
conditions including internationally; imposition of tariffs or
duties in international markets, including Israel; change in stock
exchange listing practices and ability to continue to meet minimum
listing requirements from time to time; the Company's ability to
manage costs, timing and conditions to receiving any required
testing results and certifications; results of final testing of new
products; changes in governmental plans including those related to
methods of distribution and timing and timing and nature of sales
and product returns; customer buying patterns and consumer
preferences not being as predicted given this is a new and emerging
market; material weaknesses identified in the Company’s internal
controls over financial reporting; the completion of regulatory
processes and registrations including for new products and forms;
market demand and acceptance of new products and forms; unforeseen
construction or delivery delays including of equipment and
commissioning; increases to expected costs; competitive and
industry conditions; change in customer buying patterns; and
changes in crop yields and potency. These and other risk factors
are disclosed in the Company's documents filed from time to time
under the Company’s issuer profile on the Canadian Securities
Administrators’ System for Electronic Data Analysis and Retrieval +
(“SEDAR+”) at www.sedarplus.ca and reports and other information
filed with or furnished to the United States Securities and
Exchange Commission (“SEC”) from time to time on the SEC’s
Electronic Document Gathering and Retrieval System (“EDGAR”) at
www.sec.gov, including the Company’s most recent management
discussion and analysis ("MD&A") (furnished to the SEC on Form
6-K on August 13, 2024 ) and annual information form (filed as
Exhibit 99.6 to the Company's annual report on Form 40-F for the
fiscal year ended September 30, 2023). Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this news release. The Company
disclaims any intention or obligation, except to the extent
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. Forward looking information is subject to risks and
uncertainties that are addressed in the “Risk Factors” section of
the MD&A dated August 13, 2024 and there can be no assurance
whatsoever that these events will occur.
___________________________
1 Adjusted gross margin and adjusted
EBITDA are non-IFRS financial measures not defined by and do not
have any standardized meanings under International Financial
Reporting Standards ("IFRS"), as issued by the International
Accounting Standards Board, and might not be comparable to similar
financial measures disclosed by other issuers; please refer to
"Non-IFRS Financial Measures" in this press release for more
information.
2 Pro-forma cash balance as of the close
of the two anticipated British American Tobacco ("BAT") follow-on
investment tranches in August Fiscal 2024 and February Fiscal 2025,
respectively. This pro-forma cash amount does not account for net
operational and investing cash flows expected between now and the
closing of the third and final BAT follow-on investment
tranche.
3 As of June 30, 2024 Multiple Sources
(Hifyre, Weedcrawler, provincial boards, internal modelling)
4 Adjusted gross margin and adjusted
EBITDA are non-IFRS financial measures not defined by and do not
have any standardized meanings under International Financial
Reporting Standards ("IFRS"), as issued by the International
Accounting Standards Board, and might not be comparable to similar
financial measures disclosed by other issuers; please refer to
"Non-IFRS Financial Measures" in this press release for more
information.
5 Adjusted gross margin and adjusted
EBITDA are non-IFRS financial measures not defined by and do not
have any standardized meanings under International Financial
Reporting Standards ("IFRS"), as issued by the International
Accounting Standards Board, and might not be comparable to similar
financial measures disclosed by other issuers; please refer to
"Non-IFRS Financial Measures" in this press release for more
information.
6 Pro-forma cash balance as of the close
of the two anticipated British American Tobacco ("BAT") follow-on
investment tranches in August Fiscal 2024 and February Fiscal 2025,
respectively. This pro-forma cash amount does not account for net
operational and investing cash flows expected between now and the
closing of the third and final BAT follow-on investment
tranche.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240813263446/en/
For Investor Relations enquiries: Max Schwartz, Director
of Investor Relations investors@organigram.ca
For Media enquiries: Paolo De Luca, Chief Strategy
Officer paolo.deluca@organigram.ca
Organigram (NASDAQ:OGI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organigram (NASDAQ:OGI)
Historical Stock Chart
From Oct 2023 to Oct 2024